Ceribell

CBLL · NASDAQ

$27.68+$1.68 (+6.46%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $26.00

CBLL analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy4
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $28.56 (+3.2% upside)

Low: $24.24
Now: $27.68
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

CBLL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Oct 2, 2026	Maintains	Buy	$29.00 → $33.00	48%
BTIG	Sep 11, 2026	Maintains	Buy	$30.00	56%
BTIG	Aug 18, 2026	Maintains	Buy	$28.00 → $30.00	56%
Canaccord Genuity	Aug 11, 2026	Maintains	Buy	$25.00 → $26.00	44%
BTIG	Aug 11, 2026	Maintains	Buy	$28.00	56%
Canaccord Genuity	May 12, 2026	Maintains	Buy	$28.00 → $25.00	44%
BTIG	Jan 28, 2026	Maintains	Buy	$30.00	56%
Canaccord Genuity	Dec 17, 2025	Maintains	Buy	$29.00 → $30.00	44%
BTIG	Dec 15, 2025	Maintains	Buy	$30.00	56%
JP Morgan	Nov 5, 2025	Maintains	Overweight	$21.00 → $17.00	56%

The case for and against

Updated Oct 15, 2026

Bull case

CeriBell is attractive fundamentally because it combines a first-mover point-of-care EEG platform with proprietary AI algorithms that improve speed, accuracy, and bedside usability in acute neurology, where rapid decisions materially affect outcomes. The company has translated that advantage into strong operating momentum, including Q2 gross margin of 92.3%, 32 net new accounts to 712 total, and FY26 revenue guidance of $114M-$117M, implying about 28%-31% growth. Its outlook is further supported by a broader TAM above $3.5B, recent FDA clearances for pediatric/neonate and delirium expansion, and a still-low core penetration rate of under 4%, leaving substantial room for continued adoption and utilization.

Bear case

CeriBell is exposed to a fragile clinical adoption thesis because delirium and seizure assessment remains inconsistent, subjective, and often unreliable in ICU settings where hypoactive patients are hard to detect and nurse turnover since 2020 has further weakened bedside accuracy. Its downside is also tied to execution risk, as management itself cites competitive pressure from conventional EEG and new point-of-care offerings, reimbursement and regulatory delays, and disappointing clinical results in expanded indications such as delirium and stroke. Despite rapid growth and a market-leading position, the stock remains vulnerable to subpar financial results and gross margin pressure from tariffs or supply-chain shifts, which could undermine the best-in-class margin profile the market is expecting.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.